You just read:

Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine (CAM2038) for Treatment of Opioid Addiction

News provided by

Camurus AB

14 Nov, 2016, 07:00 GMT